title: Hormonal modulation in the treatment of breast cancer.
abstract: This article explores the history of endocrine therapy for the treatment of breast cancer, the clinical evidence behind the current standards of care, and controversies that may change these standards in the future.
authors: Division of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA. kerin.adelson@mssm.edu
authors: Kerin
authors: K
authors: Adelson
authors: Doris
authors: D
authors: Germain
authors: George
authors: G
authors: Raptis
authors: Noa
authors: N
authors: Biran
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D002277:Carcinoma / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy; D011960:Receptors, Estrogen / Q000235:genetics / Q000378:metabolism
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D011960:Receptors, Estrogen